US2003232086A1PendingUtilityA1

Gel composition for the topical treatment of rashes, dermatoses and lesions

55
Priority: Sep 2, 1999Filed: Jun 25, 2003Published: Dec 18, 2003
Est. expirySep 2, 2019(expired)· nominal 20-yr term from priority
Inventors:Michael E. Mccadden
A61K 31/56A61K 31/59
55
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Composition for topical administration comprising (a) a corticosteroid, (b) a drying agent, and (c) a broad spectrum anti-fungal agent that treats both dermatophytes and yeast.

Claims

exact text as granted — not AI-modified
1 . A composition for topical administration, the composition comprising (a) a mid-potency or high-potency corticosteroid, (b) calamine, and (c) an imidazole anti-fungal agent, the composition being in the form of a gel.  
     
     
         2 . The composition of  claim 1  wherein the composition contains about 0.005% to about 0.1% by weight of a mid potency corticosteroid.  
     
     
         3 . The composition of  claim 2  wherein the mid potency steroid is selected from the group consisting of fluocinolone acetonide, hydrocortisone butyrate, hydrocdrtisone propionate, hydrocortisone valerate, and prednicarbate.  
     
     
         4 . The composition of  claim 1  wherein the composition contains about 0.0005% to about 0.05% by weight of a mid potency or high potency corticosteroid.  
     
     
         5 . The composition of  claim 4  wherein the mid potency or high potency steroid is selected from the group consisting of flumethasone pivolate, clocortolone pivolate, triamcinolone acetonide, prednicarbate, fluticasone propionate, flurandrenolide, mometasone furoate, desoximetasone, betamethasone, betamethasone dipropionate, betamethasone valerate, betamethasone propionate, betamethasone benzoate, diflorasone diacetate, fluocinonide, halcinonide, amcinonide, halobetasol propionate, and clobetasol propionate.  
     
     
         6 . The composition of  claim 5  wherein the composition comprises at least two drying agents, one of the drying agents is calamine, another is zinc oxide and the ratio of calamine to zinc oxide is about 0.5:1 to about 10:1.  
     
     
         7 . The composition of  claim 1  wherein the composition comprises at least two drying agents, one of the drying agents is calamine, another is zinc oxide and the ratio of calamine to zinc oxide is about 0.5:1 to about 10:1.  
     
     
         8 . The composition of  claim 7  wherein the imidazole anti-fungal agent is clotrimazole.  
     
     
         9 . The composition of  claim 7  wherein the imidazole anti-fungal agent is miconazole, clotrimazole, butoconazole, tioconazole, econazole, ketoconazole, oxiconizole or sulconazole.  
     
     
         10 . The composition of  claim 1  wherein the imidazole anti-fungal agent is clotrimazole.  
     
     
         11 . A process for treating diaper rash, intertrigo, atinea infection, seborrhea, psoriasis or lichen simplex chronicus, the process comprising topically applying a composition to the affected area, the composition comprising (a) a mid-potency or high-potency corticosteroid, (b) calamine, and (c) an imidazole anti-fungal agent, the composition being in the form of a gel.  
     
     
         12 . The process of  claim 11  wherein the composition contains about 0.005% to about 0.1% by weight of a mid potency corticosteroid.  
     
     
         13 . The process of  claim 12  wherein the mid potency steroid is selected from the group consisting of fluocinolone acetonide, hydrocortisone butyrate, hydrocortisone propionate, hydrocortisone valerate, and prednicarbate.  
     
     
         14 . The process of  claim 11  wherein the composition contains about 0.0005% to about 0.05% by weight of a mid potency or high potency corticosteroid.  
     
     
         15 . The process of  claim 14  wherein the mid potency or high potency steroid is selected from the group consisting of flumethasone pivolate, clocortolone pivolate, triamcinolone acetonide, prednicarbate, fluticasone propionate, flurandrenolide, mometasone furoate, desoximetasone, betamethasone, betamethasone dipropionate, betamethasone valerate, betamethasone propionate, betamethasone benzoate, diflorasone diacetate, fluocinonide, halcinonide, amcinonide, halobetasol propionate, and clobetasol propionate.  
     
     
         16 . The process of  claim 15  wherein the composition comprises at least two drying agents, one of the drying agents is calamine, another is zinc oxide and the ratio of calamine to zinc oxide is about 0.5:1 to about 10:1.  
     
     
         17 . The process of  claim 11  wherein the composition comprises at least two drying agents, one of the drying agents is calamine, another is zinc oxide and the ratio of calamine to zinc oxide is about 0.5:1 to about 10:1.  
     
     
         18 . The process of  claim 17  wherein the imidazole anti-fungal agent is clotrimazole.  
     
     
         19 . The process of  claim 17  wherein the imidazole anti-fungal agent is miconazole, clotrimazole, butoconazole, tioconazole, econazole, ketoconazole, oxiconizole or sulconazole.  
     
     
         20 . The process of  claim 11  wherein the imidazole anti-fungal agent is clotrimazole.

Join the waitlist — get patent alerts

Track US2003232086A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.